JP2021525076A5 - - Google Patents

Info

Publication number
JP2021525076A5
JP2021525076A5 JP2020565312A JP2020565312A JP2021525076A5 JP 2021525076 A5 JP2021525076 A5 JP 2021525076A5 JP 2020565312 A JP2020565312 A JP 2020565312A JP 2020565312 A JP2020565312 A JP 2020565312A JP 2021525076 A5 JP2021525076 A5 JP 2021525076A5
Authority
JP
Japan
Prior art keywords
sequence
antigen
nucleic acid
mhc class
optionally
Prior art date
Application number
JP2020565312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525076A (ja
JPWO2019226941A5 (https=
JP7554119B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033830 external-priority patent/WO2019226941A1/en
Publication of JP2021525076A publication Critical patent/JP2021525076A/ja
Publication of JPWO2019226941A5 publication Critical patent/JPWO2019226941A5/ja
Publication of JP2021525076A5 publication Critical patent/JP2021525076A5/ja
Priority to JP2024153547A priority Critical patent/JP2024178211A/ja
Application granted granted Critical
Publication of JP7554119B2 publication Critical patent/JP7554119B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020565312A 2018-05-23 2019-05-23 共有抗原 Active JP7554119B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024153547A JP2024178211A (ja) 2018-05-23 2024-09-06 共有抗原

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862675559P 2018-05-23 2018-05-23
US201862675649P 2018-05-23 2018-05-23
US62/675,559 2018-05-23
US62/675,649 2018-05-23
PCT/US2019/033830 WO2019226941A1 (en) 2018-05-23 2019-05-23 Shared antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024153547A Division JP2024178211A (ja) 2018-05-23 2024-09-06 共有抗原

Publications (4)

Publication Number Publication Date
JP2021525076A JP2021525076A (ja) 2021-09-24
JPWO2019226941A5 JPWO2019226941A5 (https=) 2022-05-27
JP2021525076A5 true JP2021525076A5 (https=) 2022-05-27
JP7554119B2 JP7554119B2 (ja) 2024-09-19

Family

ID=68617213

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565312A Active JP7554119B2 (ja) 2018-05-23 2019-05-23 共有抗原
JP2024153547A Pending JP2024178211A (ja) 2018-05-23 2024-09-06 共有抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024153547A Pending JP2024178211A (ja) 2018-05-23 2024-09-06 共有抗原

Country Status (10)

Country Link
US (1) US20210196806A1 (https=)
EP (1) EP3796927A4 (https=)
JP (2) JP7554119B2 (https=)
KR (1) KR20210013105A (https=)
CN (1) CN112368386A (https=)
AU (2) AU2019275072A1 (https=)
CA (1) CA3099644A1 (https=)
IL (1) IL278864B1 (https=)
TW (1) TW202000907A (https=)
WO (1) WO2019226941A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102643923B1 (ko) 2014-12-23 2024-03-05 이매틱스 바이오테크놀로지스 게엠베하 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
ES2983924T3 (es) 2015-03-27 2024-10-28 Immatics Biotechnologies Gmbh Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
IL280890B2 (en) * 2018-08-17 2025-10-01 Gritstone Bio Inc Antigen-binding protein that targets shared antigens
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
WO2020186064A1 (en) * 2019-03-12 2020-09-17 The General Hospital Corporation Highly networked immunogen composition
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
AU2020384374A1 (en) * 2019-11-15 2022-06-09 Seattle Project Corp. Antigen-binding proteins targeting shared neoantigens
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
EP4062177A1 (en) * 2019-11-18 2022-09-28 Epivax Therapeutics, Inc. Improved compositions and methods for shared neo-epitope vaccines
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
AU2021258191A1 (en) * 2020-04-21 2022-12-01 Seattle Project Corp. Antigen-encoding cassettes
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
KR20230046313A (ko) 2020-08-06 2023-04-05 그릿스톤 바이오, 인코포레이티드 다중에피토프 백신 카세트
JP2023541671A (ja) * 2020-09-17 2023-10-03 プロシーナ バイオサイエンシーズ リミテッド シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン
CN116710115A (zh) 2020-11-20 2023-09-05 思维疗法股份有限公司 用于优化的肽疫苗的组合物和方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US11058751B1 (en) 2020-11-20 2021-07-13 Think Therapeutics, Inc. Compositions for optimized RAS peptide vaccines
WO2022120217A2 (en) * 2020-12-03 2022-06-09 Gritstone Bio, Inc. Homologous adenoviral vaccination
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
WO2022171032A1 (zh) * 2021-02-10 2022-08-18 上海吉倍生物技术有限公司 Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体
MX2023012141A (es) * 2021-04-14 2023-11-28 Tscan Therapeutics Inc Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos.
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
CA3216276A1 (en) 2021-04-29 2022-11-03 Yardena Samuels T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
TWI804229B (zh) * 2021-09-27 2023-06-01 美商圖策智能科技有限公司 基於蛋白質突變預測的蛋白質結合自由能估測方法及系統
CN115785205B (zh) * 2022-06-10 2024-08-30 河北博海生物工程开发有限公司 肺癌特异性分子靶标09及其用途
CN115785208B (zh) * 2022-06-10 2024-07-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标01及其用途
CN115785211B (zh) * 2022-06-10 2024-09-24 河北博海生物工程开发有限公司 肺癌特异性分子靶标04及其用途
CN115785206B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标07及其用途
CN115785207B (zh) * 2022-06-10 2024-08-30 河北博海生物工程开发有限公司 肺癌特异性分子靶标02及其用途
CN115785209B (zh) * 2022-06-10 2024-08-02 河北博海生物工程开发有限公司 肺癌特异性分子靶标06及其用途
CN115785204B (zh) * 2022-06-10 2024-02-13 河北博海生物工程开发有限公司 肺癌特异性分子靶标08及其用途
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
JP2025542192A (ja) * 2022-12-23 2025-12-25 ハンミ ファーマシューティカルズ カンパニー リミテッド 複数のｋｒａｓ変異ペプチドが連結された抗原ペプチド、それをコーディングする核酸、及びその用途
CN116183907B (zh) * 2023-03-09 2025-03-25 巴迪泰（广西）生物科技有限公司 一种基于抗原捕捉磁珠技术的抗原富集与清洗方法及系统
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
WO2024254461A2 (en) * 2023-06-07 2024-12-12 Nutech Ventures Methods and compositions for vaccine development and delivery
GB202400424D0 (en) * 2024-01-11 2024-02-28 Cancer Research Tech Ltd Treatment and prevention of lung cancer
WO2025153053A1 (en) * 2024-01-17 2025-07-24 Abogen Biosciences (Shanghai) Co., Ltd. Composition and methods for inducing antigen specific immunity against kras mutant cells

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
GB8311018D0 (en) 1983-04-22 1983-05-25 Amersham Int Plc Detecting mutations in dna
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5240846A (en) 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5204253A (en) 1990-05-29 1993-04-20 E. I. Du Pont De Nemours And Company Method and apparatus for introducing biological substances into living cells
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
WO1996013597A2 (en) 1994-10-28 1996-05-09 The Trustees Of The University Of Pennsylvania Improved adenovirus and methods of use thereof
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
ATE220718T1 (de) * 1996-04-19 2002-08-15 Us Gov Sec Health Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
MXPA02006554A (es) 1999-12-28 2003-09-22 Epimmune Inc Minigenes optimizados y peptidos codificados por los mismos.
US20040248113A1 (en) * 1999-12-28 2004-12-09 Alessandro Sette Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
EP2311950A1 (en) * 2000-01-28 2011-04-20 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1
WO2004031210A2 (en) * 2002-10-03 2004-04-15 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
WO2005033265A2 (en) * 2003-04-25 2005-04-14 Epimmune Inc. Optimized multi-epitope constructs and uses thereof
ATE449105T1 (de) * 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US7332322B2 (en) * 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7283337B2 (en) 2005-03-04 2007-10-16 Headway Technologies, Inc. Abutted exchange bias design for sensor stabilization
CN101579528B (zh) 2009-06-24 2011-06-29 中国人民解放军军事医学科学院军事兽医研究所 一种hiv复合多表位dna疫苗及其应用
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
KR20190002733A (ko) 2010-12-30 2019-01-08 파운데이션 메디신 인코포레이티드 종양 샘플의 다유전자 분석의 최적화
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
TW202523682A (zh) * 2015-05-20 2025-06-16 美商博德研究所有限公司 共有之gata3相關之腫瘤特異性新抗原
RU2729116C2 (ru) * 2015-12-16 2020-08-04 Гритстоун Онколоджи, Инк. Идентификация, производство и применение неоантигенов
KR20190020098A (ko) * 2016-06-20 2019-02-27 아이에스에이 파마슈티컬즈 비.브이. 펩타이드 백신의 제형
PE20191345A1 (es) * 2016-11-23 2019-09-30 Gritstone Oncology Inc Administracion viral de neoantigenos
GB201621732D0 (en) * 2016-12-20 2017-02-01 Agricultural Research Council A multi-epitope dna vaccine for heartwater
KR102841050B1 (ko) 2017-04-19 2025-08-01 그릿스톤 바이오, 인코포레이티드 신생항원 동정, 제조, 및 용도
MX2019013259A (es) 2017-05-08 2020-01-13 Gritstone Oncology Inc Vectores de neoantigeno de alfavirus.
CN110720127A (zh) * 2017-06-09 2020-01-21 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用

Similar Documents

Publication Publication Date Title
JP2021525076A5 (https=)
JPWO2019226941A5 (https=)
JP2021524247A5 (https=)
JP7554119B2 (ja) 共有抗原
EP3177720B1 (en) Virus like particle comprising modified envelope protein e3
US20230270841A1 (en) Coronavirus vaccine
RU2019119272A (ru) Вирусная доставка неоантигенов
JP2021524247A (ja) 免疫チェックポイント阻害剤の共発現ベクター
EP3423473A2 (en) Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
JP2022512912A (ja) アルファウイルス新生抗原ベクター及びインターフェロン阻害因子
JPWO2021236854A5 (https=)
Lundstrom Alphavirus vectors for vaccine production and gene therapy
CN111630060A (zh) 用于在疾病的预防和/或治疗中使用的疫苗
BR112015023524B1 (pt) Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune
CN116096409A (zh) 编码稳定化的冠状病毒刺突蛋白的rna复制子
JP2004501646A5 (https=)
CN106459997A (zh) 用于疫苗应用的高效价病毒样囊泡的进化
JP2024510610A (ja) 人工アルファウイルス由来ｒｎａレプリコン発現系
JP2020532287A (ja) 癌の治療のためのネオアンチゲンワクチン組成物
JPWO2019226939A5 (https=)
JPWO2020097393A5 (https=)
JPWO2022032196A5 (https=)
JPWO2020243719A5 (https=)
JPWO2021003348A5 (https=)
JPWO2021216776A5 (https=)